David P. Meeker - Jun 3, 2025 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role
President and CEO, Director
Signature
/s/ Stephen Vander Stoep, Attorney-in-Fact for David Meeker
Stock symbol
RYTM
Transactions as of
Jun 3, 2025
Transactions value $
-$2,637,118
Form type
4
Date filed
6/5/2025, 04:16 PM
Previous filing
Feb 19, 2025
Next filing
Jun 13, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Meeker David P President and CEO, Director C/O RHYTHM PHARMACEUTICALS, INC., 222 BERKELEY STREET, 12TH FLOOR, BOSTON /s/ Stephen Vander Stoep, Attorney-in-Fact for David Meeker 2025-06-05 0001385155

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RYTM Common Stock Options Exercise $200K +43.6K +21.61% $4.59 245K Jun 3, 2025 Direct F1
transaction RYTM Common Stock Sale -$2.82M -43.3K -17.66% $65.04 202K Jun 3, 2025 Direct F2, F3
transaction RYTM Common Stock Sale -$18K -274 -0.14% $65.60 202K Jun 3, 2025 Direct F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RYTM Stock Option (Right to Buy) Options Exercise $0 -43.6K -100% $0.00 0 Jun 3, 2025 Common Stock 43.6K $4.59 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Includes 544 additional shares acquired under the Issuer's Employee Stock Purchase Plan.
F2 The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 plan adopted by the Reporting Person on March 3, 2025.
F3 The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $64.59 to $65.58 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $65.60 to $65.61 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The stock option is fully vested.